Company Overview and News

 
TS Wong increases stake in Excel Force

2018-10-05 thestar.com.my
The company, in a filing with Bursa Malaysia, said Wong(pic) had acquired 142,000 shares via the open market yesterday, bringing his direct stake in the company to 4.667%. His indirect interest in the company stands at 20.2%, via Asia Internet Holdings Sdn Bhd, which is the single largest shareholder in Eforce.
BSMAF 0065 1818

 
Stock With Momentum: Excel Force MSC Bhd

2018-09-21 theedgemarkets
Excel Force MSC Bhd (-ve) TRADING of shares in Excel Force MSC Bhd (fundamental: 2.55/3, valuation: 0.5/3), which made it into our momentum algorithm list yesterday for the second time this year, gained three sen or 4.05% to close at 77 sen, valuing the group at RM319.15 million.
0065

 
Stock With Momentum: Excel Force MSC Bhd

2018-08-09 theedgemarkets
Excel Force MSC Bhd (+ve) Trading of the shares in Excel Force MSC Bhd (fundamental: 1.95/3, valuation: 0.4/3) triggered our momentum algorithm as the counter closed 0.5 sen 0.76% lower at 65.5 sen. It earlier rose to 72 sen in the morning trade before retracting towards the end of afternoon trading session. Its market capitalisation stood at RM271.5 million.
0065

1
The Week Ahead: Focus on oil price and full Cabinet line-up

2018-06-18 theedgemarkets
The possible announcement of the full Cabinet line-up could be among the highlights this week, even as businesses continue to cash in on the World Cup 2018 fever and the zero-rated Goods and Services Tax (GST) “tax holiday”. There was no Cabinet meeting last Wednesday (June 13) with Prime Minister Tun Dr Mahathir Mohamad just returning from a work trip in Japan (June 11 and 12) and Hari Raya Puasa festivities on June 15 and 16.
8591 5139 9571 5797 1996 0900 5263 5098 0065 5156

4
Stocks battered by GE14 tsunami

2018-05-18 thestar.com.my
The unprecedented electoral victory by Pakatan Harapan was unfavourable to many stocks as it was favourable to others.
3204 BSMAF 0065 7078 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...